Skip to main content
Home > The Daily Extra > Top Story

Chronological Index of : Top Story

 Current Issue
  • TOP STORY: Sanofi ouster opens can of worms

    Sanofi (Euronext:SAN; NYSE:SNY) shares touched a 52-week low of $44.50 in New York on Wednesday before its ADSs closed down $2.85 (6%) to $45.22, on the news that Christopher Viehbacher had been removed as CEO, a move …

    Published on 10/29/2014
  • TOP STORY: Sovaldi sales drop on Harvoni launch

    Executives at Gilead Sciences Inc. (NASDAQ:GILD) on Tuesday were circumspect about forecasting the sales ramp for the company's HCV franchise comprising ultrablockbuster Sovaldi sofosbuvir and its newly lauched Harvoni …

    Published on 10/28/2014
  • TOP STORY: Receptos doubles up with RPC1063 in UC

    Receptos Inc. (NASDAQ:RCPT) on Monday reported that RPC1063 met the primary endpoint in a Phase II trial in a second hot disease space, ulcerative colitis (UC), and now needs to think strategically about its partnering …

    Published on 10/27/2014
  • TOP STORY: Shire sets its peer group

    With a $1.6 billion breakup fee in hand from erstwhile merger partner AbbVie Inc. (NYSE:ABBV), Shire plc (LSE:SHP; NASDAQ:SHPG) on Friday reiterated its prospects as an independent company focused on rare and specialty …

    Published on 10/24/2014
  • TOP STORY: Celgene boosts itself, Acceleron

    Celgene Corp. (NASDAQ:CELG) added $5.64 (5.9%) to $100.40 on Thursday after reporting adjusted net income of $806 million in 3Q14, up 20% from $669 million in 3Q13, and upped its revenue and EPS guidance for the year.In…

    Published on 10/23/2014
  • TOP STORY: GSK shuffles top management

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reshuffled its executive management as it prepares to integrate the vaccines business it is acquiring from Novartis AG (NYSE:NVS; SIX:NOVN) in an asset-swapping deal announced in …

    Published on 10/22/2014
  • TOP STORY: Third Point pushes for Amgen breakup

    Activist investor Third Point on Tuesday outlined a plan for increasing the valuation of Amgen Inc. (NASDAQ:AMGN) by more than 80% in the next two years. The firm wants Amgen to split into two companies, one each for "…

    Published on 10/21/2014
  • TOP STORY: NewLink lands $150M upfront from Genentech

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) acquired exclusive, worldwide rights to cancer candidate NLG919 from NewLink Genetics Corp. (NASDAQ:NLNK) for $150 million up front. NewLink is eligible for …

    Published on 10/20/2014
  • TOP STORY: Amgen sues Sanofi, Regeneron over PCSK9

    Amgen Inc. (NASDAQ:AMGN) filed a lawsuit in the U.S. District Court for the District of Delaware alleging that alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) infringes…

    Published on 10/17/2014
  • TOP STORY: Canaan closes tenth fund at $675M

    Canaan Partners closed its tenth fund, Canaan X, with $675 million. The firm expects to invest about a third of the fund, or $225 million, in healthcare, with the rest earmarked for IT. Within healthcare, the firm plans…

    Published on 10/16/2014
  • TOP STORY: FDA accelerates approval for Esbriet, Ofev

    FDA on Wednesday approved two drugs for idiopathic pulmonary fibrosis (IPF): Esbriet pirfenidone from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and Ofev nintedanib from Boehringer Ingelheim GmbH (…

    Published on 10/15/2014
  • TOP STORY: J&J vows "competitive" HCV pricing

    Johnson & Johnson CFO Dominic Caruso said the company intends to "remain competitive in the HCV category" following the approval of Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), suggesting the…

    Published on 10/14/2014
  • TOP STORY: Alnylam up on patisiran Phase II extension data

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) jumped $13.83 (19%) to $86.68 after six-month data from a Phase II study of patisiran ( ALN-TTR02) suggested the compound may have halted progression of transthyretin (TTR)-…

    Published on 10/13/2014
  • TOP STORY: FDA approves Gilead's Harvoni HCV combo

    FDA approved Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), the first oral combination therapy to treat chronic HCV genotype 1 infection that does not require interferon or ribavirin. Harvoni is …

    Published on 10/10/2014
  • TOP STORY: Achillion HCV combo has 100% SVR in Phase II

    A combination including ACH-3102 from Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) led to 100% SVR8 rates in a Phase II study to treat HCV genotype 1, according to an abstract released ahead of the American Association …

    Published on 10/9/2014
  • TOP STORY: How BMS's all-oral HCV regimen lines up

    A fixed-dose combination of daclatasvir, asunaprevir and BMS-791325 from Bristol-Myers Squibb Co. (NYSE:BMY) produced SVR12 rates of 92% in treatment-naive patients and 89% in treatment-experienced subjects in the Phase…

    Published on 10/8/2014
  • TOP STORY: BMS withdraws asunaprevir NDA

    One day prior to releasing data on regimens including its daclatasvir to treat HCV, Bristol-Myers Squibb Co. (NYSE:BMY) said it has withdrawn its NDA for asunaprevir and will no longer pursue FDA approval of a dual …

    Published on 10/7/2014
  • TOP STORY: Actavis raises stakes in ABSSSI race

    Actavis plc (NYSE:ACT) will acquire Durata Therapeutics Inc. (NASDAQ:DRTX) for $675 million in cash up front, or $23 per share, plus up to $146.5 million in regulatory and commercial milestones in the form of a …

    Published on 10/6/2014
  • TOP STORY: Salix, Cosmo abandon merger

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) and Cosmo Pharmaceuticals S.p.A. (SIX:COPN) said they have ended their merger agreement. The two companies had envisioned financial benefits from domiciling the combined entity …

    Published on 10/3/2014
  • TOP STORY: EMA adopts transparency policy

    EMA's management board unanimously adopted its clinical data transparency policy,to be introduced in two phases starting Jan. 1, 2015. In the first phase, EMA will publish clinical reports supporting MAA submissions …

    Published on 10/2/2014
  • TOP STORY: Esperion jumps on Phase IIb ETC-1002 results

    Esperion Therapeutics Inc. (NASDAQ:ESPR) said both doses of its ETC-1002 met the primary endpoint compared to ezetimibe in a Phase IIb study to treat patients with hypercholesterolemia, with or without statin …

    Published on 10/1/2014
  • TOP STORY: J&J buying Alios for $1.75B

    Johnson & Johnson (NYSE:JNJ) is acquiring Alios BioPharma Inc. (South San Francisco, Calif.) for $1.75 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus…

    Published on 9/30/2014
  • TOP STORY: CVR boosts Ambit in Daiichi Sankyo deal

    Daiichi Sankyo Co. Ltd. (Tokyo:4568) will acquire Ambit Biosciences Corp. (NASDAQ:AMBI) for up to $410 million. The deal includes $315 million in upfront cash, or $15 per share, plus $95 million in commercial milestones…

    Published on 9/29/2014
  • TOP STORY: CHMP recommends Gilead's HCV combo

    EMA's CHMP recommended marketing authorization for Harvoni sofosbuvir/ledipasvir from Gilead Sciences Inc. (NASDAQ:GILD) to treat chronic HCV infection in adults. Gilead expects a final decision from the European …

    Published on 9/26/2014
  • TOP STORY: Nicox gains on Phase III glaucoma data

    Nicox S.A. (Euronext:COX) gained EUR 0.46 (21%) to EUR 2.62 on Thursday after it said Vesneo latanoprostene bunod (formerly NCX 116, BOL-303259-X) met its primary endpoint of non-inferiority vs. timolol maleate in two …

    Published on 9/25/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993